Activity |
T-50 |
T-40 |
T-30 |
T-20 |
T-10 |
In-Life Phase |
T+10 |
T+20 |
T+30 |
T+40 |
T+50 |
T+60 |
T+70 |
| a) Initial planning T-50 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| b) Confidentiality agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
| c) Request for draft quote T-50 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| d) Approval of draft quote T-45 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| e) Initial study plan T-30 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
1) Analysis of dose solutions (method and schedule) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
4) Test and control article handling and storage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
6) Dosing: route of administration, regimen, duration |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
9) Necropsy/gross pathology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
10) Clinical chemistry parameters |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
11) Histopathology parameters |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
12) Analysis of data (statistics) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| f) Draft study protocol T-28 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
| g) Set pre-study meeting date (CRO staff) T-28 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| h) Pre-study Sponsor—CRO meeting (preferably in person, or by video or teleconference) T-14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
a) Sponsor company: technical contact, admin contact, other |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
b) CRO: technical management, study director, QA, admin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
2) Review and clarify: protocol, study background, deadlines |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| i) Protocol approval T-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| j) Sponsor transfers test article to CRO
T-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| k) Sponsor and QA review draft report T+29 to T+50 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| l) Sponsor receives final report T+60 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| m) Team review/evaluation with CRO T+70 |
|
|
|
|
|
|
|
|
|
|
|
|
|